



ASX Release

UPDATE ON SPERMSEP DEVELOPMENT

SPERMSEP DEVICE TO BE CALLED FELIX

Sydney, Thursday 29 June 2017

Memphasys (**ASX: MEM**) reports that the first two cartridges for the next generation “SpermSep” device are due to be delivered to Memphasys on Friday 30th June. Hydrix, Memphasys’ engineering development partner, is currently on budget and schedule in the manufacturing of the cartridges.

The device will be called “Felix”, a name derived from Latin meaning “joy”, replacing the former name “SpermSep”.

The device is a global first for automating the preparation of sperm for human IVF. Apart from being cost effective, quick and easy to operate, most importantly, it will select the most viable sperm from the semen sample and, unlike current processes, will not damage the sperm’s DNA.

Compared with the capacity of the prior device of 0.6 ml, the prototype cartridges will process three times the volume of semen of up to 1.8 ml, thereby increasing the market opportunity.

Once the initial two cartridges have been thoroughly tested at the Memphasys’ labs, Hydrix will be given approval to complete the order. On order completion, the functioning of the cartridges will be validated by Memphasys along with Professor John Aitken’s reproductive science research group at the University of Newcastle. They will then be on-sent for further testing and validation by our IVF clinic development partners, the Monash IVF Group, Westmead IVF and the UNSW IVF group.

On completion of these steps, Memphasys will develop the final, fully disposable cartridges that will be used in the end-product to be validated by *in-vitro* global key opinion leader (“KOL”) studies.

Subject to funding, it is anticipated that it will take approximately 6 months to start these global KOL studies, to be completed by mid-2019.

Memphasys also advises that it has appointed Mark Gell, a former non-executive director, to provide advice under a 12-month consultancy agreement on corporate strategy and investor relations.

Further, with respect to Prime, Memphasys has been advised that the Executive Chairman, Dr Hari Nair, and Managing Director, John Manus, have resigned from Prime.

For further information please contact:

Alison Coutts
Executive Chairman
+61 2 8415 7300
alison.coutts@memphasys.com

Memphasys Limited
30-32 Richmond Road
Homebush West NSW 2140

Postal Address
P.O. Box 2202
Homebush West NSW 2140

Contact Details
P +612 8415 7300
F +612 8415 7399

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556

About Memphasys

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.